Key Points
• The endogenous inhibitors of APC also inhibit other coagulation proteases rendering them unacceptable for treatment of hemophilia.
• Rationally-designed APC-specific serpins rescue thrombin generation in vitro and restore hemostasis in hemophilia mouse models.
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Introduction
Hemostasis is a crucial part of the physiological response to tissue damage. When blood components come into contact with extravascular cells and proteins, platelets accumulate and the coagulation cascade is initiated. 1 The sequential activation of zymogens to active serine proteases culminates in the formation of the effector serine protease thrombin. 2, 3 Thrombin activates platelets and cleaves fibrinogen to fibrin, the two major components of a stable blood clot. 4, 5 Thrombin also cleaves and activates the critical factors (f) VIII and V, thereby allowing the formation of the highly efficient intrinsic Xase (fVIIIa-fIXa) and prothrombinase (fVa-fXa) complexes, resulting in the burst of thrombin formation necessary to establish and maintain the integrity of the hemostatic clot (Fig. S1 ). In addition to these procoagulant activities, thrombin plays a crucial role in down-regulating its own formation by activation of the protein C anticoagulation pathway. 6 When bound to its cofactor thrombomodulin (TM), thrombin efficiently cleaves protein C to activated protein C (APC), a powerful anticoagulant that proteolytically inactivates fVIIIa and fVa, thereby shutting down the intrinsic Xase and prothrombinase complexes (Fig. S1 ).
Hemophilia A and B are X-linked genetic disorders with rates of 1:5,000 and 1:20,000 live male births. 7 The bleeding associated with these disorders is the result of a defect or deficiency in fVIII (hemophilia A) or fIX (hemophilia B), the two components of the intrinsic Xase complex. The mainstream treatment for hemophilia consists of replacement of the affected factor on-demand when bleeds occur or prophylactically. [8] [9] [10] [11] [12] [13] Prophylactic treatment is incompletely effective and only reduces the frequency of bleeds. Neither treatment regimen prevents the formation of target joints (hemophilic arthropathy), a major cause of morbidity associated with
For personal use only. on November 1, 2017 . by guest www.bloodjournal.org From hemophilia. 14 In addition, since the replacement factor is effectively a foreign protein, treatment is often associated with formation of inhibitory antibodies 15, 16 , necessitating use of a different class of therapeutics, termed 'bypassing agents' 17 . The purpose of bypassing agents is to increase thrombin generation through mechanisms independent of the intrinsic Xase complex, the most commonly used of which are fVIIa (NovoSeven), prothrombin concentrates and FEIBA (factor eight inhibitor bypassing activity). However, these agents suffer from short half-lives and show variable responses in patients. [18] [19] [20] [21] They are also less effective than replacement therapy before inhibitor formation and are not commonly used prophylactically.
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Currently all approved bypassing agents improve thrombin generation by bolstering the levels of coagulation factors. An alternative approach is to reduce the efficiency of natural anticoagulant mechanisms (e.g. using siRNA to knockdown antithrombin levels or an antibody to inhibit tissue-factor pathway inhibitor). 23, 24 The protein C system is particularly attractive because partial APC resistance reduces the frequency and severity of bleeding in hemophiliacs, with the common fV Leiden variant providing an early proof-of-concept in man. [25] [26] [27] The mode of action of an APC inhibitor is to prolong the life-span of the prothrombinase complex, thereby directly increasing thrombin generation at the site of tissue damage (Fig. S1 ).
The endogenous inhibitors of APC are members of the serpin family. 28 Serpins utilize a well-characterized mechanism of protease inhibition, where the protease recognizes a stretch of the exposed reactive center loop (RCL) as a substrate (Fig. S2 ) and is then trapped in a covalent complex following a large conformational change. 29 Several serpins are able to inhibit APC, including α 1 -antitrypsin (α 1 AT) 30 , plasminogen , and it is also capable of inhibiting procoagulant proteases such as thrombin, fXa and fVIIa. 32, 33 The other circulating serpins are also inefficient APCinhibitors that lack specificity. It is therefore unlikely that the administration of an endogenous inhibitor of APC would have the desired hemostatic effect. Herein we describe the engineering and characterization of a serpin specific for APC, and show that it is effective in increasing thrombin generation in vitro and normalizing hemostasis in hemophilia B mice.
Methods

Protein expression and purification
Human PCI with its N-terminal 21 residues truncated (Δ21, first residue is Ala22) was expressed from E. coli and purified as described 34 
Determination of inhibition constants
Second-order rate constants of protease inhibition were measured by a discontinuous method under pseudo first-order conditions, using at least a five-fold molar excess of serpin over protease. All reagents were diluted into assay buffer (20 mM Tris pH 7.4, 100 mM NaCl, 0.2% BSA, 0.1% PEG8,000). For reactions with APC and fXa, 2.5 mM CaCl 2 was included in the buffer. Reactions were incubated at room temperature, and stopped for each time-point by the addition of the chromogenic substrate appropriate for the protease used (S2238 for thrombin, S2366 for APC and fXIa, and S2222 for fXa). The slope of the linear part of A 405 (absorbance at 405 nm) over time gave the residual protease activity at each time-point. The apparent first-order rate constant k obs was calculated from the slope of a plot of the natural log of residual protease activity over time. k obs was measured for at least five different serpin concentrations and plotted against serpin concentration. The slope of this linear plot gave the second-order rate constant k 2 . For each determination the standard error of the slope is given.
SDS-PAGE of complex formation
Serpins and human plasma-derived proteases were diluted into 20 mM Tris pH 7.4, 100 mM NaCl prior to the experiment. For reactions with APC and fXa, 2.5 mM CaCl 2 was included in the buffer. Serpin and protease were incubated at equimolar concentrations (1 μ M final), and samples were removed at the indicated time-points.
SDS sample buffer was added with (reducing) or without (non-reducing) 50 mM DTT and samples were place in a boiling water bath to stop the reaction. Samples were then run on SDS-PAGE and reactions products were by Coomassie staining.
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PT and aPTT
Fresh frozen human plasma from three different donors were mixed to generate pooled plasma. For the PT assays, plasma was diluted 2-fold in 20 mM Tris pH 7.4, 100 mM NaCl, 2.5 mM CaCl 2 . 50 μl diluted plasma was mixed with 50 μl serpin and incubated for 60 s. 100 μl PT reagent (TriniClot PT Excel) was then added to initiate the clotting reaction. For aPTT assays, 50 μl plasma was mixed with 50 μl serpin diluted in 20 mM Tris pH 7.4, 150 mM NaCl. 100 μl aPTT reagent (Triniclot automated aPTT reagent) was added and the reaction incubated for 5 min. 100 μl 25 mM CaCl 2 was added to start the clotting reaction. Time to clot formation for both assays was measured on a Stago Start coagulation analyzer. All reactions were carried out at 37˚C and used a final serpin concentration of 5 μM.
Thrombin generation assays
Normal human plasma was purchased from George King Biomedical. 40 μl plasma was mixed with 10 μl RB reagent (TF low/phospholipids mix, TechnoClone) and 5 μl protein sample diluted in 20 mM HEPES pH 7.4, 150 mM NaCl, 0.1% BSA. 50 μl 1 mM Z-Gly-Gly-Arg-AMC (BaChem) in 15 mM CaCl 2 was added to initiate the reaction. Fluorescence was read using 360 nm excitation and 460 nm emission wavelengths. Fluorescence units were converted to thrombin concentration using a TGA calibration kit (TechnoClone). Data were analyzed using the Technothrombin TGA evaluation spreadsheet (TechnoClone). All reactions were performed at 37˚C.
Tail clip assays
Tail clip assays were performed essentially as described. 35 Briefly, male WT or HB mice (BALB/c) (8-16 weeks of age) were anesthetized using 2% isoflurane at 2
For personal use only. on November 1, 2017. by guest www.bloodjournal.org From ml/min and weighed. Mice were injected through the tail vein with 200 μl PBS or α 1 AT variant diluted into PBS. Five minutes after injection, the tail was cut at 3 mm diameter, placed into a tube filled with prewarmed saline solution (37ºC) and blood collected for 10 min. Collection tubes were centrifuged and the saline solution suctioned off. Lysis buffer (150 mM NH 4 Cl, 10 mM KHCO 3 , 1 mM EDTA) was added and red cells were allowed to lyse for 10 min at room temperature. Samples were centrifuged and absorbance of the supernatant at 575 nm determined to measure hemoglobin content. A standard curve using known volumes of blood was constructed to allow calculation of total volume blood loss.
Intravital microscopy
The real-time in vivo imaging experiments were performed essentially as described. 35 Briefly, male HB mice aged (~12 weeks of age) were anesthetized and the cremaster muscle exposed and stretched across an intravital microscopy tray. Mice were infused with 10 μ g rat anti-CD41 Alexa 555 labeled antibody and 10 μ g anti-fibrin Alexa 647 labeled antibody in a total volume of 100 μ l. This was followed by infusion of 100 μ l PBS or 100 μ l α 1 AT variant diluted in PBS. Laser injury was induced in cremaster arterioles using a pulse-nitrogen dye laser through the microscope objective. Both brightfield and fluorescence images were collected for 3-4 min. Data were analyzed using Slidebook 5 software (Intelligent Imaging Innovations).
Results
Engineering Specificity
The main determinant of serpin specificity is the RCL sequence in and around the scissile bond. In the standard substrate nomenclature the scissile bond is denoted P1-P1´, with residues N-terminal numbered P2, P3, etc., and those C-terminal numbered P2´, P3´, etc. 36 All clotting proteases, including APC, favor an arginine in the P1 position due to Asp189 (chymotrypsin template numbering) at the base of the S1
pocket. We examined the structures of APC and thrombin bound to the same covalent inhibitor (D-Phe-Pro-Arg-chloromethylketone (PPACK)) to see if differences in shape and properties in other parts of the substrate binding site might be exploited to confer specificity for APC (Fig. 1A) . PPACK binds in an identical fashion in the two structures, with the P1 Arg deep in the S1 pocket, the P2 Pro in the S2 pocket, and the D-Phe in the aryl biding site (S4 pocket). However, PPACK is buried in the active site cleft of thrombin, whereas the active site of APC is wide open, especially on either side of the P1 residue (the S2 and S1´ sites). This is due primarily to the difference in size of the 60-loop in APC and thrombin; APC has a single insertion relative to chymotrypsin and thrombin has a nine-residue insert. The 60-loop in thrombin has been well characterized, and acts as a hydrophobic cap that restricts the S2 and S1´
pockets, favoring small hydrophobic amino acids like Gly and Pro at S2 and Ser in S1´3 7 . In addition, the S1´ site is also more acidic in APC than in thrombin due to the side chain of Asp60a in the position of Lys60h in thrombin. We previously reported a high-resolution crystal structure of the PCI-thrombin complex (3B9F) that revealed the details of the RCL interaction with the active site of thrombin 34 . Superposition of APC on thrombin in this structure shows the features observed with PPACK are largely preserved, namely that APC is permissive of large side chains at the S2 and S1´ sites, and would interact favorably with basic residues (Fig. 1B) . We hypothesized, therefore, that bulky residues at the P2 and P1´ positions would be disfavored by thrombin, and that basic residues at these positions might additionally
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Specificity of PCI RCL Lys variants
Individual and combined P2 and P1´ lysine variants were constructed on the PCI scaffold as described in Methods. The RCL of wild-type PCI has a P2 Phe, P1 Arg and P1´ Ser, so we refer to wild-type as FRS. Separate and combined P2 and P1´ Lys variants are referred to as KRS, FRK and KRK. To evaluate the effect of the mutations on the inhibitory activity of PCI, variants were incubated with either thrombin ( Fig. 2A) or APC (Fig. 2B ) and the reaction products run on SDS-PAGE ( Fig. 2 and Fig. S3 ). This method allows simultaneous evaluation of both inhibitory and substrate behavior (Fig. S2) . Wild-type PCI rapidly formed complex with thrombin, with complete inhibition in about one minute. APC inhibition was considerably slower, with the reaction completed after about 4 hours. The P2 Lys (KRS) mutation slowed complex formation with thrombin, requiring 30 minutes to achieve full inhibition. The P1´ Lys mutation (FRK) essentially abolished thrombin inhibition, although the PCI was consumed as a substrate. The inhibitory profiles of these variants for APC were essentially identical to wild-type PCI, indicating that the substitutions were tolerated, but did not improve APC recognition. The combined P2, P1´ Lys mutations (KRK) resulted in complete loss of activity against thrombin, similar to what was found for the P1´ variant, but appeared to slow inhibition of APC, approximately doubling the time require to achieve full inhibition relative to wildtype. Second-order rate constants for the inhibition of thrombin and APC by the PCI variants were determined (Table 1) , and agree with the qualitative SDS-PAGE results.
Both the FRK and KRK variants of PCI exhibited a substantial increase in specificity for APC over thrombin (1600-and 400-fold, respectively), however the rates of APC inhibition remained low.
Specificity of α 1 -Antitrypsin RCL Lys variants α 1 -Antitrypsin (α 1 AT) is the most prevalent serpin in the blood, circulating at a concentration of around 2 g/L. 38, 39 It has a Met at the P1 position, and therefore targets chymotrypsin-type serine proteases including neutrophil elastase and cathepsin G. The Pittsburgh mutation, P1 Met-to-Arg, has been observed in a few patients who generally experience severe bleeding due to the switching of specificity toward the trypsin-type serine proteases, including the clotting factors thrombin and fXa. 40, 41 However, α 1 AT Pittsburgh is also a potent inhibitor of APC, with a rate constant 100-times than that of PCI. 30 We therefore hypothesized that α 1 AT Pittsburgh might serve as a better template for creating an APC-specific serpin, using the Lys mutations identified from our work with PCI.
Lysine mutations were made individually and in combination at P2 and P1´ in α 1 AT Pittsburgh (α 1 AT has a Pro at the P2 position and a Ser at the P1´ position, PRS).
Rates of inhibition of APC, thrombin, fXa and fXIa, were measured, and the results are given in Table 2 . As seen with PCI, each single Lys mutation dramatically reduced inhibition of thrombin, ~5800-fold for KRS α 1 AT and ~1700-fold for PRK To determine if the observed decrease in rate of procoagulant protease inhibition was due to increased substrate behavior, reactions were visualized by SDS-PAGE (Fig. 3 ).
For these experiments, fIXa and thrombin:TM were also included (Fig. S4) . KRK α 1 AT rapidly formed a covalent complex with APC (Fig. 3A) , but no complex formation or cleavage was observed with thrombin, even after 4 hours (Fig. 3B ).
Small amounts of complex was observed with fXa ( Fig. 3C ) and fXIa (Fig. S4F) , consistent with the results from the kinetic studies. For fIXa, only a hint of inhibitory complex was observed (Fig. S4E ). The addition of thrombomodulin (TM) to thrombin had no effect on the ability of thrombin to react with KRK α 1 AT (Fig. S4D ). These results indicate that KRK α 1 AT has a better inhibitory profile than KRK PCI, and justify its selection as the candidate anti-APC serpin for efficacy studies.
Effect of KRK α 1 AT on Clotting Times and Thrombin Generation in vitro
For KRK α 1 AT to be a useful hemostatic agent it must be devoid of any residual anticoagulant activity. We therefore spiked normal pooled plasma with PRS (control) or KRK α 1 AT and conducted prothrombin time (PT) and activated partial thromboplastin time (aPTT) assays (Table 3 ). The PRS α 1 AT control increased clotting times in both assays, however, addition of KRK α 1 AT to normal plasma had no effect on the PT and only a marginal effect on the aPTT, consistent with some residual activity against fXIa ( Table 2 ). The residual anti-fXa activity of KRK α 1 AT also appears to be too slow (116 M -1 s -1 , Table 2 ) to affect clotting times in these assays. We concluded that KRK α 1 AT does not possess any relevant anticoagulant activity.
To assess the procoagulant activity of KRK α 1 AT we employed a thrombin generation assay (TGA) in the absence and presence of thrombomodulin (TM), with PRS α 1 AT
For personal use only. on November 1, 2017. by guest www.bloodjournal.org From as control (Fig. 4 and Fig. S5 ). Two concentrations of TM were chosen empirically:
one that resulted in a ~50% reduction in thrombin generation, and one that essentially abolished thrombin generation. The control anticoagulant PRS α 1 AT completely inhibited thrombin generation in normal plasma when added at a concentration of 0.5 µM (Fig. S5A) . Consistent with results from the PT assay, KRK α 1 AT had no effect on thrombin generation when added to normal pooled plasma (Fig. 4A) . However, when TM was added, KRK α 1 AT dose-dependently increased thrombin generation ( Fig. 4B and 4C) . Similar results were obtained in a TGA using plasma from hemophilia A and B patients (Fig. 4D, 4E , Fig. S6 and Fig. S7 ).
Effect of KRK α 1 AT on Clotting in vivo
The high sequence identities between human and mouse APC and thrombin (72% and 87%, respectively) suggest that the relevant features of the active sites are preserved.
This was confirmed by comparing structures of human 42 and mouse thrombin 43 ( Fig.   S8A ), and by comparing a model of mouse APC with the crystal structure of human APC 44 ( Fig. S8B) . Mouse thrombin did not react with KRK α 1 AT (Fig. S9) , and inhibition of mouse APC was preserved (2-fold reduction in rate constant, Table S2 ).
In addition, KRK α 1 AT dose-dependently increased thrombin generation in mouse hemophilia B plasma spiked with TM (Fig. S10) . We concluded that mouse models of hemostasis could be used to test the in vivo efficacy of KRK α 1 AT.
Two assays were used to assess the ability of KRK α 1 AT to promote hemostasis in a hemophilia B mouse: tail clip and intravital laser injury. In the tail clip assay, the tail was transected and blood was collected for 10 min after administration of either KRK α 1 AT or PBS, and total volume blood loss was calculated from a standard hemoglobin curve after red cell lysis. 35 In this model, KRK α 1 AT dose-dependently decreased the For personal use only. on November 1, 2017. by guest www.bloodjournal.org From blood loss (Fig. 5A) , with the highest dose (15 mg/kg) reducing bleeding to the level of WT mice. The effect of KRK α 1 AT was also assessed using the cremaster arteriole laser injury model. 45 Clot formation was visualized by fluorescent microscopy, following deposition of platelets (red) and fibrin (green) with time. KRK α 1 AT dosedependently increased in the amount of platelet (Fig. 5B ) and fibrin deposition (Fig.   5C ). Example images taken as snapshots from representative recorded videos are shown in Fig. S11 . At the 7.5 mg/kg dose of KRK α 1 AT, stable clots (platelets and fibrin) occurred in 55% of injuries, compared to 0% when only PBS was given. For the higher dose (15 mg/kg), stable clots were observed in 85% of injuries (Table 4) .
Fluorescence quantitation showed a shorter lagtime for fibrin deposition at the higher dose (Fig. 5C ).
Discussion
This study was motivated by the observation that bleeding frequency and severity is reduced in hemophilia A patients who co-inherit the fV Leiden mutation. [25] [26] [27] These observations were supported by crossing hemophilia A and B mice with fV Leiden mice and conducting tail clip and intravital microscopy studies. 46 We therefore hypothesized that a serpin with specificity for APC might be an effective hemostatic agent.
The mechanism of all hemophilia treatments is to increase the amount of thrombin generated at sites of vascular damage. This is generally achieved by adding missing factors or by boosting the concentration of either the enzymes or substrates that lead to the production of thrombin. The fV Leiden mutation and, to a potentially greater extent, direct APC inhibition increases thrombin generation by allowing alreadyformed prothrombinase more time to function.
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Our goal was to engineer a serpin that would inhibit APC with a rate constant of greater than 1×10 4 M -1 s -1 , but without appreciable inhibition of any relevant procoagulant protease. Based on differences in features of the active sites of thrombin and APC, we chose to alter the two residues flanking the primary specificitydetermining P1 residue (P2 and P1´). Mutating these to Lys in PCI had the desired effect on selectivity, but the rate of inhibition of APC was unacceptably low.
Although the rate of inhibition was increased by adding heparin (data not shown), the relevance of glycosaminoglycans in mediating APC inhibition by PCI in vivo is unclear.
We therefore decided to change the serpin scaffold to α 1 AT Pittsburgh, which is known to rapidly inhibit APC and procoagulant proteases. As with the PCI template, the KRK mutations in the RCL of α 1 AT abrogated inhibition of the tested coagulation proteases whilst maintaining an ability to rapidly inhibit APC. Importantly, coagulation was not inhibited by the addition of KRK α 1 AT to normal or hemophilia plasma, even at concentrations of 5 μ M. KRK α 1 AT did, however, retain some residual inhibitory activity against fXIa, reflected in slightly prolonged aPTTs.
However, the main function of fXIa in coagulation is the activation of fIX to support formation of the intrinsic Xase complex. Deficiency in either fVIII or fIX, the basis of hemophilia, therefore renders fXIa redundant.
It is important to note that the studies described here used protein purified from an E.
coli expression system, perhaps explaining the relatively high doses required for efficacy in the mouse models. Although the activity of α 1 AT is not affected by glycosylation 47 , its absence will reduce the protein's half-life. 48 Therefore the actual exposure of KRK α 1 AT in the efficacy experiments is likely to be substantially lower than what would be expected based on dose. PK and efficacy studies using
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One major advantage of choosing α 1 AT as the scaffold anti-APC serpin is its 5-7 day half-life in the circulation. 49 Additionally, in contrast to current bypassing agents, which are administered intravenously, the subcutaneous route of administration for KRK α 1 AT might also be available. Studies in rabbits showed that the pharmacodynamics of subcutaneously administered plasma human α 1 AT were comparable to intravenous administrated protein. 50 The risk for cross-reacting antibodies developing in response to KRK α 1 AT is also likely to be low because wildtype α 1 AT is present at a high concentration (~2 g/L) in plasma 38, 39 , and immune tolerance to a protein is strongly related to its endogenous level 51, 52 . Therefore, Tables   Table 1 
